Objective:To assess the effect of Shexiang Baoxin Pill（SXBXP）for labour angina pectoris.Methods:Effect of 66 patientstreated withconven tional treatment or conventional treatment plus SXBXP were observed and compare...Objective:To assess the effect of Shexiang Baoxin Pill（SXBXP）for labour angina pectoris.Methods:Effect of 66 patientstreated withconven tional treatment or conventional treatment plus SXBXP were observed and compared with^(99m) TC-MIBI singlepho tonemissi on computerized tomography（SPECT）target cardiograph to estimate is chemia my ocardial area.Results:The total effectiverate was much higher in patients treated with SXBXP than that in patients treated with conventional treatment only（87.8%vs.56%,P＜0.05）.The effective rate on ECG in the two group swas 70.7% and 52%respectively,with out significant statistical difference between them（P＞0.05）.While significant difference was observed in is chemiaarea of my ocardiali mage between the two groups after treatment,18.2±8.2%vs23.8±9.8%,P<0.05.Moreover,there currence of anginapect or is and cardiaceven twerealsolessin the SXBXPgroup.Conclusion:the SXBXP was effective for labourangina pectoris.展开更多
Background:Preliminary studies have indicated that Shexiang Baoxin Pill(MUSKARDIA)has a coronary artery dilation effect and increases the coronary blood flow,relieving the symptoms of angina.This study aimed to evalua...Background:Preliminary studies have indicated that Shexiang Baoxin Pill(MUSKARDIA)has a coronary artery dilation effect and increases the coronary blood flow,relieving the symptoms of angina.This study aimed to evaluate the benefit of MUSKARDIA on patients with stable coronary artery disease(CAD)and diabetes mellitus(DM).Methods:This was a subgroup analysis of a multicenter,randomized,placebo-controlled phase IV trial.CAD patients with a medical history of DM or baseline fasting blood glucose(FBG)≥7.0 mmol/L were grouped according to the treatment(standard therapy plus MUSKARDIA or placebo).The primary outcome was major adverse cardiovascular events(MACEs),which was the composite outcome of cardiovascular death,non-fatal myocardial infarction,and non-fatal stroke.The secondary outcome was the composite outcome of all-cause death,non-fatal myocardial infarction,non-fatal stroke,hospitalization for unstable angina or heart failure,and coronary angioplasty.Results:MACEs occurred in 2.6%(9/340)and 4.8%(18/376)of patients in the MUSKARDIA and placebo groups,respectively(P=0.192).Secondary composite outcome was significantly less frequent with MUSKARDIA than with placebo(15.3%[52/340]vs.22.6%[85/376],P=0.017).Risk of MACEs(hazard ratio[HR]=0.69,95%confidence interval[CI]:0.31-1.57)was comparable between two groups.In patients with uncontrolled DM(≥4 measurements of FBG≥7 mmol/L in five times of follow-up),the risk of secondary outcome was significantly lower with MUSKARDIA(5/83,6.0%)than with placebo(15/91,16.5%)(HR=0.35,95%CI:0.13-0.95).Conclusion:As an add-on to standard therapy,MUSKARDIA shows a trend of reduced MACEs in patients with stable CAD and DM.Furthermore,MUSKARDIA may reduce the frequency of all-cause death,hospitalization,and coronary angioplasty in this population,especially in those with uncontrolled DM.Trial Registration:ChiCTR.org.cn,ChiCTR-TRC-12003513.展开更多
文摘Objective:To assess the effect of Shexiang Baoxin Pill（SXBXP）for labour angina pectoris.Methods:Effect of 66 patientstreated withconven tional treatment or conventional treatment plus SXBXP were observed and compared with^(99m) TC-MIBI singlepho tonemissi on computerized tomography（SPECT）target cardiograph to estimate is chemia my ocardial area.Results:The total effectiverate was much higher in patients treated with SXBXP than that in patients treated with conventional treatment only（87.8%vs.56%,P＜0.05）.The effective rate on ECG in the two group swas 70.7% and 52%respectively,with out significant statistical difference between them（P＞0.05）.While significant difference was observed in is chemiaarea of my ocardiali mage between the two groups after treatment,18.2±8.2%vs23.8±9.8%,P<0.05.Moreover,there currence of anginapect or is and cardiaceven twerealsolessin the SXBXPgroup.Conclusion:the SXBXP was effective for labourangina pectoris.
基金Shanghai Science and Technology Committee(No.09dZ1971400)
文摘Background:Preliminary studies have indicated that Shexiang Baoxin Pill(MUSKARDIA)has a coronary artery dilation effect and increases the coronary blood flow,relieving the symptoms of angina.This study aimed to evaluate the benefit of MUSKARDIA on patients with stable coronary artery disease(CAD)and diabetes mellitus(DM).Methods:This was a subgroup analysis of a multicenter,randomized,placebo-controlled phase IV trial.CAD patients with a medical history of DM or baseline fasting blood glucose(FBG)≥7.0 mmol/L were grouped according to the treatment(standard therapy plus MUSKARDIA or placebo).The primary outcome was major adverse cardiovascular events(MACEs),which was the composite outcome of cardiovascular death,non-fatal myocardial infarction,and non-fatal stroke.The secondary outcome was the composite outcome of all-cause death,non-fatal myocardial infarction,non-fatal stroke,hospitalization for unstable angina or heart failure,and coronary angioplasty.Results:MACEs occurred in 2.6%(9/340)and 4.8%(18/376)of patients in the MUSKARDIA and placebo groups,respectively(P=0.192).Secondary composite outcome was significantly less frequent with MUSKARDIA than with placebo(15.3%[52/340]vs.22.6%[85/376],P=0.017).Risk of MACEs(hazard ratio[HR]=0.69,95%confidence interval[CI]:0.31-1.57)was comparable between two groups.In patients with uncontrolled DM(≥4 measurements of FBG≥7 mmol/L in five times of follow-up),the risk of secondary outcome was significantly lower with MUSKARDIA(5/83,6.0%)than with placebo(15/91,16.5%)(HR=0.35,95%CI:0.13-0.95).Conclusion:As an add-on to standard therapy,MUSKARDIA shows a trend of reduced MACEs in patients with stable CAD and DM.Furthermore,MUSKARDIA may reduce the frequency of all-cause death,hospitalization,and coronary angioplasty in this population,especially in those with uncontrolled DM.Trial Registration:ChiCTR.org.cn,ChiCTR-TRC-12003513.
